KR20010023085A - 미립자 분산액 형태의 고체 제약 투여 형태 - Google Patents

미립자 분산액 형태의 고체 제약 투여 형태 Download PDF

Info

Publication number
KR20010023085A
KR20010023085A KR1020007001704A KR20007001704A KR20010023085A KR 20010023085 A KR20010023085 A KR 20010023085A KR 1020007001704 A KR1020007001704 A KR 1020007001704A KR 20007001704 A KR20007001704 A KR 20007001704A KR 20010023085 A KR20010023085 A KR 20010023085A
Authority
KR
South Korea
Prior art keywords
peg
drug
particulate
hpc
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020007001704A
Other languages
English (en)
Korean (ko)
Inventor
아이작 게브라-셀라시에
Original Assignee
로즈 암스트롱, 크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 로즈 암스트롱, 크리스틴 에이. 트러트웨인
Publication of KR20010023085A publication Critical patent/KR20010023085A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020007001704A 1997-08-21 1998-07-29 미립자 분산액 형태의 고체 제약 투여 형태 Ceased KR20010023085A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21
US60/056,195 1997-08-21
PCT/US1998/015693 WO1999008660A1 (en) 1997-08-21 1998-07-29 Solid pharmaceutical dosage forms in form of a particulate dispersion

Publications (1)

Publication Number Publication Date
KR20010023085A true KR20010023085A (ko) 2001-03-26

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007001704A Ceased KR20010023085A (ko) 1997-08-21 1998-07-29 미립자 분산액 형태의 고체 제약 투여 형태

Country Status (17)

Country Link
US (1) US20010048946A1 (cg-RX-API-DMAC10.html)
EP (1) EP1011640A1 (cg-RX-API-DMAC10.html)
JP (1) JP2001515029A (cg-RX-API-DMAC10.html)
KR (1) KR20010023085A (cg-RX-API-DMAC10.html)
AR (1) AR018252A1 (cg-RX-API-DMAC10.html)
AU (1) AU8600098A (cg-RX-API-DMAC10.html)
BR (1) BR9811972A (cg-RX-API-DMAC10.html)
CA (1) CA2292586C (cg-RX-API-DMAC10.html)
CO (1) CO4960652A1 (cg-RX-API-DMAC10.html)
GT (1) GT199800136A (cg-RX-API-DMAC10.html)
HN (1) HN1998000115A (cg-RX-API-DMAC10.html)
NZ (1) NZ502869A (cg-RX-API-DMAC10.html)
PA (1) PA8458101A1 (cg-RX-API-DMAC10.html)
PE (1) PE109599A1 (cg-RX-API-DMAC10.html)
SV (1) SV1998000104A (cg-RX-API-DMAC10.html)
WO (1) WO1999008660A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987551B (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
JPH06511291A (ja) * 1991-08-02 1994-12-15 ウィルコム タフティング ピーティーワイ リミテッド 房付け方法及び房付けシステム
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002024168A1 (fr) * 2000-09-25 2002-03-28 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide medicinale
ATE293439T1 (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
CN1681479A (zh) * 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DK1830817T3 (da) * 2004-12-30 2013-04-02 Pf Medicament Stabil, fast dispersion af et derivat af vinca-alkaloid og fremgangsmåde til fremstilling heraf
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
NZ585116A (en) * 2005-05-10 2011-12-22 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
JP2010513324A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
PT2309987E (pt) * 2008-07-03 2012-12-13 Novartis Ag Processo para granulação por fusão
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
CA2848493A1 (en) 2011-09-14 2013-03-21 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンa物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
SG43179A1 (en) * 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CA2292586C (en) 2006-02-14
GT199800136A (es) 2000-02-11
BR9811972A (pt) 2000-08-15
PE109599A1 (es) 1999-12-19
ZA987551B (en) 1999-02-23
HN1998000115A (es) 1999-06-02
SV1998000104A (es) 1999-07-02
PA8458101A1 (es) 2001-12-14
CO4960652A1 (es) 2000-09-25
AR018252A1 (es) 2001-11-14
WO1999008660A1 (en) 1999-02-25
NZ502869A (en) 2002-10-25
AU8600098A (en) 1999-03-08
EP1011640A1 (en) 2000-06-28
CA2292586A1 (en) 1999-02-25
US20010048946A1 (en) 2001-12-06
JP2001515029A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
CA2292586C (en) Solid pharmaceutical dosage forms in form of a particulate dispersion
US6677362B1 (en) Solid pharmaceutical dispersions
AU2003215449B2 (en) Immediate release pharmaceutical granule compositions and a continuous process for making them
JP6522853B2 (ja) Somcl−9112固体分散体、その製造方法およびそれを含むsomcl−9112固体製剤
PL191181B1 (pl) Sposób wytwarzania doustnego preparatu itrakonazolu i doustny preparat itrakonazolu
CN108495620A (zh) 包含苯基氨基嘧啶衍生物的药物组合物
EP1289560A1 (en) Novel solid dispersion compositions
Tripathy et al. Solid dispersion: A technology for improving aqueous solubility of drug
Breitkreutz et al. Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder
CA2812665C (en) Pharmaceutical composition for treating hcv infections
MXPA99011317A (en) Solid pharmaceutical dosage forms in form of a particulate dispersion
TW202604488A (zh) 包含索托克拉固體分散體之醫藥調配物及其製備方法
WO2026052846A1 (en) Pharmaceutical formulation comprising apalutamide
JPH03169814A (ja) ニフェジピン持続性製剤の製造法
CN119522100A (zh) 含有德拉马尼的固体分散体
TR2021005753T (tr) Seli̇neksorun yeni̇ kati di̇spersi̇yonlari
HK1186982B (en) Pharmaceutical composition for treating hcv infections

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030326

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050127

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20051020

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20050721

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20060221

Appeal identifier: 2005101007170

Request date: 20051020

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20051118

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20051020

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050328

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20030326

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J801 Dismissal of trial

Free format text: REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20051020

Effective date: 20060221

PJ0801 Rejection of trial

Patent event date: 20060221

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20060221

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2005101007170

Request date: 20051020